Merck, Qiagen bring cervical cancer screening closer to the grassroots
September 29th, 2009 | Vanguard
As part of the first ever collaboration between a vaccine manufacturer and a molecular diagnostics company, Merck & Co., Inc. and Qiagen N.V. are initiating a $600 million collaboration to increase access to vaccinations against the Human Papilloma Virus (HPV) and HPV DNA testing in select GAVI-eligible countries.
Leave a Comment